Markets have been really bad at coming with solutions (a) for chronically vulnerable groups, (b) for problems which develop over too long a time period to become urgent, and (c) by replacing reactive efforts with proactive efforts. MF seems to check all three of those boxes, while making sense as a business. Cool.

Can you say anything about how you expect these kinds of proactive diagnostics to interact with the existing insurance ecosystem, which tends to pay for diagnosis but varies a lot on treatment?